플라스틱 담도 스텐트 시장 : 스텐트 설계, 재질, 직경, 적응증, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Plastic Biliary Stents Market is projected to grow by USD 172.72 million at a CAGR of 6.15% by 2032.

Plastic Biliary Stents Market Introduction

Plastic biliary stents remain a core device category in therapeutic endoscopic retrograde cholangiopancreatography (ERCP), supporting bile drainage in patients with benign biliary strictures, malignant biliary obstruction, post-operative bile leaks, choledocholithiasis-related obstruction, and transplant-associated biliary complications. These polymer-based devices, commonly manufactured from polyethylene or comparable medical-grade plastics, are widely used because they are cost-effective, familiar to endoscopists, available in multiple diameters and configurations, and suitable for temporary biliary drainage where scheduled exchange is clinically appropriate.

Demand for plastic biliary stents is supported by the persistent global burden of hepatobiliary and pancreatic diseases, expanding access to interventional endoscopy, and the continued need for lower-cost alternatives to metal stents in selected indications. Plastic biliary stents compete with self-expandable metal stents and emerging biodegradable technologies; however, they retain strong clinical relevance in benign disease management, short-term palliation, staged procedures, and healthcare systems where affordability, procedural flexibility, and reliable device availability are decisive purchasing factors.

Transformative Shifts in the Plastic Biliary Stents Landscape

The plastic biliary stents landscape is being reshaped by clinical preference for patient-specific drainage strategies rather than one-device-fits-all approaches. Guidelines from major gastrointestinal endoscopy societies support plastic stents in several benign indications, while also emphasizing planned exchange because of biofilm formation, sludge accumulation, and occlusion risk. This has increased demand for plastic biliary stents with improved flow characteristics, anti-migration designs, radiopaque markers, and compatible delivery systems that can reduce procedure time and support predictable placement.

Another major shift is the rise of advanced ERCP capacity in tertiary hospitals, specialty gastroenterology networks, and selected ambulatory surgery centers. Healthcare providers are standardizing procurement around stent reliability, availability of multiple French sizes and lengths, compatibility with guidewires and duodenoscopes, and dependable supply continuity. At the same time, value-based purchasing is pressuring manufacturers to demonstrate consistent clinical performance, post-market quality, and total episode-of-care advantages, not only low unit price.

Cumulative Impact of Artificial Intelligence on Plastic Biliary Stents

Artificial intelligence is beginning to influence the plastic biliary stents market through endoscopy workflow optimization, imaging support, and predictive analytics rather than through the stent itself. AI-assisted image interpretation in gastrointestinal endoscopy is advancing rapidly, and the same digital infrastructure can support earlier recognition of biliary obstruction patterns, stricture complexity, and procedure-related risk factors. As AI-enabled endoscopy platforms mature, they are expected to improve pre-procedure planning and support more consistent selection of stent type, stent size, and exchange interval.

The cumulative impact of AI is also visible in hospital operations and medical device manufacturing. Predictive inventory management can reduce stockouts of high-use plastic biliary stent sizes, while data-driven quality systems can help manufacturers monitor complaint trends, migration events, occlusion patterns, and lot-level performance. For industry leaders, AI creates an opportunity to connect device utilization data with clinical outcomes, supporting stronger evidence generation for plastic biliary stents in benign biliary strictures, bile leaks, and short-term drainage indications.

Key Regional Insights for Plastic Biliary Stents

Asia-Pacific is one of the most important environments for plastic biliary stents due to large patient populations, expanding ERCP training, and rising investment in hospital endoscopy units across China, India, Japan, South Korea, Australia, and ASEAN markets. Demand is supported by increasing diagnosis of pancreaticobiliary disorders, broader health insurance coverage in selected countries, and the need for cost-efficient biliary drainage devices across public and private hospitals. Japan, South Korea, and Australia show advanced endoscopy quality standards, while China and India are expanding access through tertiary-care development and specialist training.

North America remains a high-value regional environment characterized by advanced therapeutic endoscopy adoption, established reimbursement pathways, strong procedural capacity, and broad availability of trained interventional gastroenterologists. Europe shows steady demand driven by guideline-based care, mature hospital procurement systems, robust endoscopist training, and regulatory emphasis on clinical evidence and post-market surveillance. Latin America demonstrates improving uptake as Brazil and Mexico expand tertiary-care gastroenterology capacity and private hospital networks. The Middle East is investing in specialty hospitals and medical tourism infrastructure, particularly in GCC countries, whereas Africa remains an emerging region where access to ERCP, trained specialists, referral systems, and reliable device distribution are key determinants of plastic biliary stent adoption.

Key Group Insights Across Global Healthcare Blocs

ASEAN markets are gaining importance as Thailand, Indonesia, Malaysia, Vietnam, Singapore, and the Philippines expand endoscopy services and referral networks for hepatobiliary disease. The region's device mix is influenced by affordability, distributor reach, hospital tendering practices, and physician preference for familiar plastic biliary stent platforms in temporary drainage procedures. GCC countries are more strongly shaped by premium hospital infrastructure, imported device availability, medical tourism, and demand for international-quality interventional gastroenterology services.

The European Union benefits from harmonized medical device regulation under the EU Medical Device Regulation, which increases emphasis on clinical evidence, post-market surveillance, traceability, and quality documentation for biliary stents and ERCP accessories. BRICS markets combine major patient-burden potential with diverse pricing and access dynamics, especially in China, India, and Brazil, where public and private hospital systems often follow different procurement pathways. G7 countries account for premium demand due to advanced hospital systems, specialist density, reimbursement maturity, and strong quality expectations, while NATO countries collectively reflect established procurement standards, supply-chain resilience priorities, and mature clinical practice patterns for therapeutic ERCP devices.

Key Country Insights for Plastic Biliary Stents

The United States leads demand through high ERCP procedure capacity, broad availability of interventional gastroenterologists, established hospital and ambulatory endoscopy infrastructure, and structured reimbursement for therapeutic biliary procedures. Canada shows stable adoption supported by publicly funded care pathways and regional referral centers, while Mexico benefits from expanding private hospital networks, tertiary-care investment, and cross-border medical service capacity. Brazil is Latin America's most influential country for plastic biliary stents because of its large hospital base and specialist concentration, although access varies between public and private systems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature demand for plastic biliary stents through guideline-driven practice, established endoscopy infrastructure, and standardized procurement. Germany is particularly influential because of its hospital density, strong medical technology ecosystem, and advanced endoscopy capability, while France, Italy, Spain, and the United Kingdom emphasize clinical governance, quality assurance, and structured referral pathways. Russia remains relevant due to its large hospital network and specialist centers, although supply-chain complexity, regulatory localization, and import dynamics can influence product availability.

In Asia-Pacific, China and India offer major procedure-volume potential due to large populations, rising diagnosis of pancreaticobiliary disease, and increasing access to advanced endoscopy in urban tertiary hospitals. Japan and South Korea are technologically sophisticated markets with strong endoscopic expertise, high quality expectations, and demand for reliable device performance, while Australia demonstrates stable adoption through specialist centers, structured reimbursement, and well-developed referral systems. Across these countries, plastic biliary stent adoption is strongest where ERCP access, trained clinicians, appropriate exchange protocols, and reliable device supply converge.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize product portfolios that address real-world ERCP needs, including a complete range of diameters, lengths, shapes, radiopaque visibility, and delivery-system compatibility. Manufacturers can strengthen differentiation by investing in anti-occlusion surface research, anti-migration features, kink-resistant designs, clear labeling, and packaging that supports fast, sterile workflow in high-volume endoscopy units.

Commercial teams should align pricing and evidence strategies with indication-specific use. Plastic biliary stents should be positioned clearly for benign biliary strictures, bile leaks, temporary drainage, short-term decompression, and staged procedures, while evidence generation should focus on patency, migration, exchange compliance, procedure efficiency, adverse-event monitoring, and total cost of care. Companies should also build resilient regional distribution, maintain safety stock for high-turnover sizes, strengthen post-market surveillance, and provide physician education on appropriate stent selection and scheduled exchange planning.

Research Methodology

This executive summary is based on a structured secondary and analytical research approach using verified clinical, regulatory, and market-relevant sources. Inputs include peer-reviewed gastroenterology literature, society guidelines from recognized endoscopy organizations, regulatory frameworks for medical devices, hospital procurement considerations, manufacturer product information, and epidemiological indicators linked to pancreaticobiliary disease burden.

The methodology emphasizes triangulation across clinical practice patterns, technology trends, reimbursement environments, regional healthcare infrastructure, regulatory requirements, and competitive positioning. Insights were validated for consistency with established ERCP practice, known device characteristics of plastic biliary stents, and observable shifts in endoscopy service delivery. No unsupported market sizing, market share, or forecasting claims are included; conclusions focus on evidence-backed demand drivers, adoption dynamics, and strategic implications.

Conclusion

Plastic biliary stents continue to play an essential role in biliary drainage despite competition from metal and emerging stent technologies. Their affordability, procedural flexibility, broad clinical familiarity, and suitability for temporary use make them indispensable in benign biliary disease management, bile leak treatment, short-term decompression of obstructed bile ducts, and staged therapeutic ERCP.

Future performance in the plastic biliary stents market will depend on the ability of manufacturers to improve device reliability, support evidence-based selection, and maintain supply resilience across diverse healthcare systems. As AI-enabled endoscopy, data-driven procurement, stricter regulatory expectations, and post-market performance monitoring evolve, organizations that combine clinical utility with operational excellence will be best positioned to strengthen adoption across global plastic biliary stent applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Plastic Biliary Stents Market, by Stent Design

• 7.1. Pigtail
• 7.2. Straight
• 7.3. Curved
• 7.4. Wedge

8. Plastic Biliary Stents Market, by Material

• 8.1. Polyethylene
• 8.2. Polyurethane
• 8.3. Polytetrafluoroethylene
• 8.4. Silicone

9. Plastic Biliary Stents Market, by Diameter

• 9.1. 7-8 Fr
• 9.2. 9-10 Fr
• 9.3. Above 10 Fr
• 9.4. Up to 6 Fr

10. Plastic Biliary Stents Market, by Indication

• 10.1. Malignant Obstruction
• 10.2. Benign Conditions
  • 10.2.1. Bile Leaks
  • 10.2.2. Stone-Related Obstruction
• 10.3. Acute Cholangitis

11. Plastic Biliary Stents Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Plastic Biliary Stents Market, by Distribution Channel

• 12.1. Direct Sales
• 12.2. Distributor Network
• 12.3. Online Sales

13. Plastic Biliary Stents Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Plastic Biliary Stents Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Plastic Biliary Stents Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Boston Scientific Corporation
• 17.2. Cook Group Inc.
• 17.3. Olympus Corporation
• 17.4. Merit Medical Systems, Inc.
• 17.5. Micro-Tech (Nanjing) Co., Ltd.
• 17.6. CONMED Corporation
• 17.7. Medtronic plc
• 17.8. ENDO-FLEX GmbH
• 17.9. Medorah Meditek Pvt. Ltd.
• 17.10. Hobbs Medical Inc.
• 17.11. Q3 Medical Devices Limited
• 17.12. Ace Medical Devices Pvt. Ltd.
• 17.13. Advin Health Care
• 17.14. B. Braun Melsungen AG
• 17.15. Bassil Scientific Private Limited
• 17.16. Becton, Dickinson and Company
• 17.17. Changzhou Health Microport Medical Devices Co., Ltd.
• 17.18. Duomed Group
• 17.19. ELLA-CS, s.r.o.
• 17.20. Focuz Medical
• 17.21. JDmeditech Co., Ltd.
• 17.22. Leufen Medical GmbH
• 17.23. M.I.Tech Co., Ltd.
• 17.24. Surgimedex